Presentation at the MedTech Summit 2018 in Brussels concerning the new EU regulatory regime for economic operators in the supply chain of medical devices and IVDs
Presentation at the Advamed MedTech conference in Boston on 25 September regarding the state of implementation of the EU Medical Devices Regulation MDR, and what companies can still do before its date of application on 26 May 2020
This presentation describes regulatory hurdles to keep in mind when acquiring / selling medical devices companies with CE certificates to prevent them from becoming invalid.
Presentation at the MedTech Summit 2018 in Brussels concerning the new EU regulatory regime for economic operators in the supply chain of medical devices and IVDs
Presentation at the Advamed MedTech conference in Boston on 25 September regarding the state of implementation of the EU Medical Devices Regulation MDR, and what companies can still do before its date of application on 26 May 2020
This presentation describes regulatory hurdles to keep in mind when acquiring / selling medical devices companies with CE certificates to prevent them from becoming invalid.
Presentation at the 29-30 January 2014 Informa Medical Devices Revision conference in Brussels regarding developments in relation to the Eudamed database and its rule in the new EU medical devices system
Liability insurance requirements under the new EU Medical Devices Regulation ...Erik Vollebregt
Presentation at the Q1 conference on 23 May about the new liability regime likely to be imposed under the new new EU Medical Devices Regulation and In Vitro Diagnostics Regulation.
Use of left over samples under the IVDR and GDPRErik Vollebregt
Presentation on the RAPS Convergence 2017 about the use of left over samples in performance evaluation under the In Vitro Diagnostics Regulation (IVDR) and under the General Data Protection Regulation (GDPR)
Presentation delivered at the RMD 2016 conference (European Symposium on the New Agreed Draft Regulations on Medical Devices) in Prague on 7 November 2016
New legal obligations and liability under MDR and IVDRErik Vollebregt
Presentation at the MedTech Summit in Amsterdam on 19 June 2017 on the product liability regime under the MDR and IVDR, its nexus with the EU Product Liability Directive and its impact on other provisions in the MDR / IVDR
Q1 Medical Devices Regulation - practical consequences for manufacturersErik Vollebregt
Presentation at the Q1 MDR conference in Arlington on 12 July 2018 about the consequences of the EU Medical Devices Regulation for US companies in the medtech industry
Annex I under the EU MDR, General Safety and Performance Requirements, outlines some broad requirements that are applicable to all devices. Manufacturers need to carefully read and understand each requirement since only some of them will apply to any given device...
Presentation at the Dutch Sterilisation Association annual meeting about how the new EU Medical Devices Regulation affects the sterilisation industry specifically.
General Data Protection Regulation (GDPR) - Cross-Border Data Transferspi
The General Data Protection Regulation will Impact all health data processing companies because of the growing importance of customer and patient data to the manufacturer’s business. All companies have to be compliant by 25th May 2018.
This presentation gives an overview of all the possibilities included in the GDPR to allow Cross-Border Data Transfers to third countries.
Presentation at the 29-30 January 2014 Informa Medical Devices Revision conference in Brussels regarding developments in relation to the Eudamed database and its rule in the new EU medical devices system
Liability insurance requirements under the new EU Medical Devices Regulation ...Erik Vollebregt
Presentation at the Q1 conference on 23 May about the new liability regime likely to be imposed under the new new EU Medical Devices Regulation and In Vitro Diagnostics Regulation.
Use of left over samples under the IVDR and GDPRErik Vollebregt
Presentation on the RAPS Convergence 2017 about the use of left over samples in performance evaluation under the In Vitro Diagnostics Regulation (IVDR) and under the General Data Protection Regulation (GDPR)
Presentation delivered at the RMD 2016 conference (European Symposium on the New Agreed Draft Regulations on Medical Devices) in Prague on 7 November 2016
New legal obligations and liability under MDR and IVDRErik Vollebregt
Presentation at the MedTech Summit in Amsterdam on 19 June 2017 on the product liability regime under the MDR and IVDR, its nexus with the EU Product Liability Directive and its impact on other provisions in the MDR / IVDR
Q1 Medical Devices Regulation - practical consequences for manufacturersErik Vollebregt
Presentation at the Q1 MDR conference in Arlington on 12 July 2018 about the consequences of the EU Medical Devices Regulation for US companies in the medtech industry
Annex I under the EU MDR, General Safety and Performance Requirements, outlines some broad requirements that are applicable to all devices. Manufacturers need to carefully read and understand each requirement since only some of them will apply to any given device...
Presentation at the Dutch Sterilisation Association annual meeting about how the new EU Medical Devices Regulation affects the sterilisation industry specifically.
General Data Protection Regulation (GDPR) - Cross-Border Data Transferspi
The General Data Protection Regulation will Impact all health data processing companies because of the growing importance of customer and patient data to the manufacturer’s business. All companies have to be compliant by 25th May 2018.
This presentation gives an overview of all the possibilities included in the GDPR to allow Cross-Border Data Transfers to third countries.
Decision CAMP 2014 - Tobias Vigmostad - Digitalizing Business and Legislative...Decision CAMP
The focus of the presentation will be to explain what challenges the Directorate of Immigration in Norway (UDI) faced when trying to move from the traditional legal casework towards an electronic process industry while also maintaining sound legal control of the automated rules. (UDI is the central agency in the Norwegian Immigration Administration.)
The project delivered tools centered on BRS and extensive use of RMA. UDI continually uses these tools to implement new business rules and to improve the business processes and decisions.
The presentation will also touch upon key events in the past that influenced the decision to externalize business rules from the application level and compare how two different systems handled the same legal rule changes.
The key to the project’s success was to build a solution where the legal caseworkers themselves could manage and update the rules in the system, and continue to build new rules for decision support, and how this process over time transforms itself into standard decisions, a necessary stage before going into fully automated decisions.
The presentation will finally focus on the necessity for users to get experience with rules and how they work, and how that inspires new and better policies, which in turn transforms into new business rules. A key success factor is a short time to market for new rules and that the business rules were managed by the business people.
Managing New Requirement for Economic Operator RegimeErik Vollebregt
Presentation of new economic operator regime under the new EU Medical Devices and IVDs Regulations, delivered at the Q1 Medical Devices Regulation conference on 16 July 2019
Innovative indkøb i sundheds- og plejesektoren kan bruges som redskab til at skabe værdifulde og bæredygtige velfærdsløsninger.
Disse præsentationer giver et bud på, hvordan dette kan gøres i praksis og tager på forskellig vis fat på værdien i dialog.
Præsentationerne blev vist d.20.november 2014 i forbindelse med en nordisk konference støttet af Nordic Innovation.
On 04 April 2020, I had the pleasure of doing a webinar for Dhruva Advisors LLP's, the leading tax and regulatory services' firm's principals and associates on "Arbitration". We covered the arbitral process and interface of tax and arbitrations, particularly India's BIT arbitrations that arose from tax disputes.
Thank you to Dinesh Kanabar and Vishal Gada for the collaboration.
Developing strategies for contract adherence in medical devices cro contractsErik Vollebregt
This presentation was delivered at the Outsourcing in Clinical Trials: Medical Devices Europe 2016 conference in München on 17 February 2016. It covers do's and don'ts for CRO contracts in the medical devices sector.
Buried somewhere in the longest piece of legislation ever is the No Surprises Act. Signed into law on December 27, 2020, it expands restrictions on charging out-of-network rates for certain services. Discover what it means for your business: https://bit.ly/3cfmHg4
Settlement Agreements, Refreshing Law ltd slides, March 2020James Cheetham
Covering the requested topic of settlement agreements, and how to maximise their potential. The slides were originally for an event on the 24th March 2020, and due to COVID-19, this has been adapted into a podcast found here: https://yolkrec.podbean.com/e/hr-insights-settlement-agreements-march-2020/
3D medtech printing under EU Medical Devices Directive and under future Medic...Erik Vollebregt
3D medtech printing conference maastricht presentation discussing 3D medtech printing under EU Medical Devices Directive and under future Medical Devices Regulation
EU cybersecurity requirements under current and future medical devices regula...Erik Vollebregt
Presentation delivered at Q1 MEDICAL DEVICE CYBERSECURITY RISK MITIGATION conference in Washington on 25 July 2016 concerning EU cybersecurity requirements under current and future medical devices regulation
Presentation about transparency under the new MDR and IVDR at Informa Medtech Summit in Clinical evaluations and investigations for medical devices track
Changes in device classification under the EU Medical Devices and In Vitro Di...Erik Vollebregt
Presentation at the Q1 Intensive MDR/IVDR Readiness
and Transition Management Workshop about classification changes under the EU Medical Devices and In Vitro Diagnostic Regulation
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
2. Agenda
• The ability to challenge: Can you challenge the legal decisions of your
Notified Body?
• Susceptibility to freedom of Information applications
• When is changing a Notified Body allowed?
• Legal advice on involuntary change of your Notified Body
3. Notified body regulation under
(AI)MDD, IVDD, MDR and IVDR
• CE marking has been a very successful public – private cooperation for
market access with many advantages, but also some disadvantages
• Nature of legal relationship with notified bodies is private law
agreement with mandatory legal elements overseen by national
competent authorities
• Very big changes with introduction Chapter 4 and Annex VII in the MDR
and IVDR
• As a result: MDR and IVDR notified body application process still
mostly stuck in application pipeline:
4. Can you negotiate your agreement
with a notified body?
• Certification agreement is part of the
joint assessment of the notified body
and blessed by the notifying Member
State (See Annex VII, § 4.3)
• Notified body has absolutely no
interest or obligation to negotiate
about it and it would get them in
trouble to for discriminating
customers
5. When do you have an agreement
with your notified body
• Sooner than you may think!
• Remember: you cannot apply for conformity assessment with
more than one NB per product at a time
• Don’t let your notified body lock you in before you realise
• One notified body excludes all others
• You won’t be able to change anymore without consequences
6. Can you challenge the legal
decisions of your Notified Body?
• One of the big problems under EU medical devices law (both directives
and regulations) is that there is no clear legal recourse
• Notified bodies must have internal appeals procedure
• When appeals procedure is exhausted, recourse depends on
national law
• Varies considerably from one Member State to the other
• US manufacturers: don’t send in the lawyers immediately
• You will ruin your chances to a practical solution
7. Can you challenge the legal
decisions of your Notified Body?
• Only real legal recourse option under MDR / IVDR directly is article 51
(2) MDR / 47 (2) IVDR – dispute about classification
• shall be referred for a decision to the competent authority of the
Member State in which the manufacturer / AR has its registered
place of business.
• Where the notified body concerned is established in a Member
State other than that of the manufacturer, the competent authority
shall adopt its decision after consultation with the competent
authority of the Member State that designated the notified body.
8. Susceptibility to freedom of
information applications
• Notified bodies have confidentiality obligations but not all information
they have is covered by this
• Authorities will have a lot of the information that notified bodies have, so
this may be obtained through national freedom of information requests
• Notified bodies may be in scope of local freedom of information law too
9. When is changing a Notified Body
allowed?
• Changing a notified body is always allowed but not always clever
• Directives had NBOG voluntary change procedure
• Art. 58 MDR / 53 IVDR – voluntary change of notified body
procedure requires handover agreement
• Guidance in MDCG 2019-6 v2 Questions and answers:
• Requirements relating to notified bodies, § IV.4
10. Legal advice on involuntary
change of your Notified Body
• A lot of opportunities for that:
• Brexit, Swixit and Turkxit
• Notified body does not make it through joint assessments for MDR
and/or IVDR
• Article 46 MDR / article 42 IVDR has procedure, but directives do not
11. Thanks for your attention!
Erik Vollebregt
Axon Lawyers
Piet Heinkade 183
1019 HC Amsterdam
T +31 88 650 6500
M +31 6 47 180 683
E erik.vollebregt@axonlawyers.com
@meddevlegal
B http://medicaldeviceslegal.com
READ MY BLOG:
http://medicaldeviceslegal.com